ArticleCanadian journal of ophthalmology. Journal canadien d'ophtalmologie2011
Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease.
Article in Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 49 citations in OpenAlex.
- The assessment of the concentration of candidate cytokines in response to conjunctival-exposure of atmospheric low-temperature plasma in an animal model.BMC ophthalmology · 2021Article
- A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists.Pulmonary therapy · 2021Review
- Cytokines that Modulate the Differentiation of Th17 Cells in Autoimmune Uveitis.Journal of immunology research · 2021Review
- Recent advances in the management of non-infectious posterior uveitis.International ophthalmology · 2020Review
- Optimising drug therapy for non-infectious uveitis.International ophthalmology · 2019Review
- Tofacitinib for refractory uveitis and scleritis.American journal of ophthalmology case reports · 2019Article
- Update in treatment of uveitic macular edema.Drug design, development and therapy · 2019Review
- Management of chronic ocular sarcoidosis: challenges and solutions.Clinical ophthalmology (Auckland, N.Z.) · 2018Review
- Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review.Rheumatology international · 2018Review
- An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.Orphanet journal of rare diseases · 2017Review
- Knitting the Threads of Silk through Time: Behçet's Disease-Past, Present, and Future.International journal of rheumatology · 2017Review
- Article
- The Use of Biologic Therapies in Uveitis.Clinical reviews in allergy & immunology · 2015Review
- New Immunosuppressive Therapies in Uveitis Treatment.International journal of molecular sciences · 2015Review
- The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis.Paediatric drugs · 2015Review
- Cytokines and Biologics in non-infectious autoimmune uveitis: bench to bedside.Indian journal of ophthalmology · 2014Review
- A Review of Systemic Biologics and Local Immunosuppressive Medications in Uveitis.Journal of ophthalmic & vision researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
objectiveSafety and efficacy of daclizumab during an 11-year period.
designStructured, retrospective chart review.
participantsThirty-nine patients.
methodsPatients with chronic, noninfectious intermediate and/or posterior uveitis.
resultsThirty-nine patients (78 eyes) were treated for a mean of 40.3 months. Visual acuity improved by ≥2 lines in the better eye in 7 patients (18.4%) and worsened by 2 lines in 6 patients (15.8%) with a mean of 2.8 Snellen lines of vision lost per eye. Six eyes with vitreous cell less than grade 2 lost 2 lines of vision and 7 eyes with less than grade 2 vitreous cell improved 2 lines. Mean number of immunosuppressive medications per patient decreased from 1.89 medications/patient to 1.17 medications/patient. The average number of periocular injections per patient was 1.46 (range, 0-9). The mean number of flares was 2.05/patient (range, 0-12), with the rate being 0.62 flares per patient-year. Four patients developed cancer during the course of this study. Mean time to onset of malignancy was 26 months and the mean age in this group was 49 years.
conclusionsDaclizumab demonstrated efficacy in the reduction of concomitant immunosuppressive medication, stabilization of visual acuity, and the prevention of uveitic flares in most cases. Dermatologic complications were the most frequently observed adverse event in our series. Four patients developed solid tumor malignancies during this 11-year period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.